B-Cell Maturation Antigen
"B-Cell Maturation Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on mature B-LYMPHOCYTES. It has specificity for B CELL ACTIVATING FACTOR and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053301
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.226
|
| Concept/Terms |
B-Cell Maturation Antigen- B-Cell Maturation Antigen
- B Cell Maturation Antigen
- Maturation Antigen, B-Cell
- Receptors, Tumor Necrosis Factor, Member 17
- Tumor Necrosis Factor Receptor Superfamily, Member 17
- B Cell Maturation Protein A
- BCMA Protein
|
Below are MeSH descriptors whose meaning is more general than "B-Cell Maturation Antigen".
Below are MeSH descriptors whose meaning is more specific than "B-Cell Maturation Antigen".
This graph shows the total number of publications written about "B-Cell Maturation Antigen" by people in this website by year, and whether "B-Cell Maturation Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "B-Cell Maturation Antigen" by people in Profiles.
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
-
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 08 09; 13(1):117.
-
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther. 2023 04; 29(4):255-258.
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 01; 20(1):49-62.
-
Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci. 2022 Nov 03; 23(21).
-
Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022; 13:876339.
-
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med. 2021 07; 11(7):e491.
-
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica. 2021 01 01; 106(1):173-184.
-
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021 01; 35(1):255-258.
-
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019 Oct; 6(10):e521-e529.